|1.||Manea, Marilena: 14 articles (12/2015 - 04/2007)|
|2.||Orbán, Erika: 7 articles (05/2015 - 04/2009)|
|3.||Mező, Gábor: 7 articles (05/2015 - 01/2012)|
|4.||Szabó, Ildikó: 5 articles (12/2015 - 04/2009)|
|5.||Vincze, Borbála: 5 articles (12/2015 - 04/2007)|
|6.||Mezo, Gábor: 5 articles (01/2012 - 04/2007)|
|7.||Kapuvári, Bence: 4 articles (12/2015 - 04/2007)|
|8.||Marquardt, Andreas: 4 articles (05/2015 - 01/2012)|
|9.||Sobhon, Prasert: 4 articles (09/2013 - 02/2008)|
|10.||Sretarugsa, Prapee: 4 articles (09/2013 - 02/2008)|
|1.||Prostatic Neoplasms (Prostate Cancer)
10/01/2013 - "Based on these observations, different cytotoxic GnRH-III bioconjugates have recently been synthesized; preliminary in vitro studies suggest that these compounds might represent a new promising treatment strategy for prostate cancer."
01/01/2015 - "Our results demonstrated that both Dau-GnRH-III and Dau-[4Lys(Ac)]-GnRH-III were rapidly internalized into DU145 prostate cancer cells and exerted a significant cytostatic effect. "
01/01/2012 - "We synthesized 21 lGnRH-III analogs with rational amino acid substitutions and studied their effect on PC3 and LNCaP prostate cancer cell proliferation. "
01/01/2015 - "Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor."
11/01/1998 - "The inhibitory effect of GnRH-III on growth of cancer cells was specific and direct since the peptide did not have endocrine activity in the concentration range found to be effective in anticancer assays. "
12/01/2015 - "[Studying the tumor growth inhibitory effect of modified GnRH-III-anthracycline bioconjugates in subcutaneous vs. orthotopic models in vivo]."
04/01/2013 - "These features reveal the advantages of lGnRH-III and its derivatives for use in cancer therapy. "
10/01/2012 - "The bioconjugate containing Lys(nBu) in position 4 was taken up most efficiently by the cancer cells and exerted higher in vitro cytostatic effect than the previously developed GnRH-III((4)Lys(Ac), (8)Lys(Dau = Aoa)) or the parent GnRH-III(Dau = Aoa) bioconjugate. "
01/01/2012 - "A possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of the bioconjugates would be the attachment of more than one chemotherapeutic agent to one GnRH-III molecule. "
|3.||Breast Neoplasms (Breast Cancer)
04/01/2007 - "GnRH-III was reported to have selective FSH-releasing activity in rats and significant anticancer potency on human breast cancer cells. "
03/01/2005 - "Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth."
01/01/2000 - "We synthesized the analogs of GnRH-III with effective selective antitumor activity which does not alter the ovarian cycle of rats but inhibits the colony-formation of human breast cancer cell lines and has a significant antiproliferative effect. "
11/01/2006 - "Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?"
10/10/1997 - "Following the observation that the activity of gonadotropin-releasing hormone III (GnRH-III) in the suppression of growth of MDA-MB-231 and MCF-7 breast cancer cells surpasses that of GnRH and other analogs thereof, analogs of GnRH-III were synthesized to investigate the structural basis for the improved antitumor activity. "
|4.||Ganglion Cysts (Ganglion)
09/01/2013 - "In the subesophageal ganglion, lGnRH-III-ir was detected in medium-sized neurons and in the subesophageal neuropil. "
10/01/2011 - "Our immunohistochemical observations showed sex differences in the number of GnRH3 immunoreactive neurons in mature tilapia; males had a greater number of GnRH3 neurons in the terminal ganglion than females. "
11/01/2010 - "In addition, a small number of type 2 neurosecretory cells (NS2) in cerebral ganglion showed lGnRH-III-ir. "
03/01/2008 - "GnRH3 perikarya were observed migrating along their own fibres from the olfactory region to the preoptic area (POA) via the terminal nerve ganglion and the ventral telencephalon. "
03/01/2006 - "We found that all forebrain gnrh3 neurons, extending from the terminal nerve ganglion to the anterior mesencephalon, arise from the olfactory region and that trigeminal ganglion neurons express gnrh3. "
|5.||Body Weight (Weight, Body)
10/01/2005 - "Each of nine barrows (body weight: 85-90 kg; age: 207 days) received 2 ml saline (S-barrow), followed by 150 microg l-GnRH-III (1.6-1.7 microg/kg body weight) dissolved in 2 ml saline intramuscularly 7 days later. "
11/01/1997 - "Four successive injections, 3 to 4 days apart, of lamprey GnRH-III at 0.1 or 0.2 microg/g body weight induced ovulation in 100 or 88% of lampreys, respectively, compared to 21% in controls by Day 31. "
04/01/2009 - "Our data indicate that the daunorubicin-GnRH-III conjugate had a lower toxic effect than the free daunorubicin and it was essentially nontoxic up to 15 mg (Dau content)/kg body weight. "
01/01/2004 - "In Experiments 2-4, Latin Square designs were utilized in vivo to examine whether physiological and hormonal milieu regulate putative selective effects of lGnRH-III. In Experiments 2 and 3, ovariectomized cows with basal levels of estradiol only (Experiment 2) or in combination with luteal phase levels of progester-one (Experiment 3) were injected with mGnRH and lGnRH-III (0.055, 0.11, 0.165 and 1.1 microg/kg body weight (BW) and saline. "
|2.||Gonadotropin-Releasing Hormone (GnRH)
|4.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|6.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)